Author:
Cao Guorui,Zhang Shaoyun,Wang Yixuan,Xu Hong,Quan Songtao,Cai Litao,Feng Wei,Yao Junna,Tan Honglue,Pei Fuxing
Abstract
Abstract
Background
The efficacy and safety of tranexamic acid (TXA) in reducing blood loss following total knee arthroplasty (TKA) in patients with osteoarthritis have been widely confirmed. However, there is still a paucity of the evidences regarding the effectiveness of TXA in patients with rheumatoid arthritis (RA). The purpose of the study is to explore the efficacy and safety of intravenous TXA on blood loss and transfusion risk following simultaneous bilateral TKA (SBTKA) in patients with RA.
Methods
As a multicenter retrospective study, a total of 74 patients diagnosed with RA who underwent SBTKA were assigned into TXA group (15 mg/kg intravenous TXA before skin incision, n = 50) and control group (no TXA use, n = 24). The primary outcomes were total blood loss (TBL) and intraoperative blood loss (IBL). The secondary outcomes were hemoglobin (Hb) and hematocrit (Hct) drop on postoperative day 3, transfusion rate and volume, ambulation time, length of stay, hospitalization expenses and the incidence of complications.
Results
The mean TBL, IBL and transfusion volume in TXA group were significantly lower than those in control group. The Hb and Hct drop on postoperative day 3 in control group were higher than those in TXA group (p<0.05). The similar trend was detected on transfusion rate, ambulation time and length of stay. The incidence of complications and hospitalization expenses did not differ significantly between the two groups (p>0.05).
Conclusions
TXA could effectively reduce blood loss, decrease transfusion risk, shorten ambulation time and length of stay following SBTKA in patients with RA, without increasing the risk of complications.
Funder
National Natural Science Foundation of China
National Health and Family Planning Commission of the People’s Republic of China (CN) program
Publisher
Springer Science and Business Media LLC
Subject
Orthopedics and Sports Medicine,Rheumatology
Reference42 articles.
1. Britsemmer K, Ursum J, Gerritsen M, van Tuyl LH, van Schaardenburg D. Validation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: slight improvement over the 1987 ACR criteria. Ann Rheum Dis. 2011;70(8):1468–70.
2. Hawley DJ, Wolfe F. Pain, disability, and pain/disability relationships in seven rheumatic disorders: a study of 1,522 patients. J Rhuematol. 1991;18(10):1552–7.
3. Jin S, Li M, Fang Y, Li Q, Liu J, Duan X, Liu Y, Wu R, Shi X, Wang Y, et al. Chinese Registry of rheumatoid arthritis (CREDIT): II. Prevalence and risk factors of major comorbidities in chinese patients with rheumatoid arthritis. Arthritis Res therapy. 2017;19(1):251.
4. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care. 2008;14(4):234–54.
5. Baek JH, Lee SC, Kim JW, Ahn HS, Nam CH. Inferior outcomes of primary total knee arthroplasty in patients with rheumatoid arthritis compared to patients with osteoarthritis. Knee Surg sports Traumatol arthroscopy: official J ESSKA. 2022;30(8):2786–92.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献